Abstract TMP7: Efficacy And Safety Of Intravenous Tirofiban Combined With Endovascular Therapy For The Treatment Of Basilar Artery Occlusion Due To Large-artery Atherosclerotic

Background: This study aimed to evaluate whether intravenous tirofiban can improve the functional outcome without promoting risk of intracerebral hemorrhage (ICH) in patients with basilar artery occlusion (BAO) due to large-artery atherosclerotic (LAA) receiving endovascular therapy (EVT). Methods: Consecutive patients with acute BAO duet to LAA within 24 h who underwent EVT and had tirofiban treatment from the BASILAR Registry study were enrolled. All eligible patients were dichotomized into tirofiban and non-tirofiban subgroups according the use of intravenous tirofiban. The primary efficacy outcome was the favorable functional outcome (defined as mRS score of 3 or less), Safety outcomes were mortality within 90 days and intracranial hemorrhage (ICH) within 48 hours. Results: A total of 417 patients were included in this study, of which 275 were in the tirofiban group and 142 were in the non-tirofiban group. After adjusting for multiple factors, patient in the tirofiban group were 1.17 (95% confidence interval [CI], 1.05-1.31) times more likely to achieve favorable outcome at 90 days than those in the non-tirofiban group. The mortality of the tirofiban group was higher than that of the non-tirofiban group (40.7% vs. 58.5%; adjusted risk ratio, 0.61; 95% CI, 0.74-0.89; P <0.001). The 1-year follow-up results were also similar to that at 90 days. Any ICH occurred in 19 (7.1%) patients in the tirofiban group, which was lower than that of 22 (15.8%) in the non-tirofiban group (adjusted risk ratio, 0.45; 95% CI, 0.26-0.68; P=0.004) and symptomatic ICH occurred in 15 (5.2%) patients in the tirofiban group, which was lower than that of 17 (12.2%) in the non-tirofiban group (adjusted risk ratio, 0.40; 95% CI, 0.21-0.76; P=0.005). Conclusions: Tirofiban may associated with improve 90-day favorable outcomes and reduced mortality risk decreased incidence of ICH in patients with BAO due to LAA receiving EVT. The treatment effect of tirofiban may be maintained for one year.